Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide - PubMed (original) (raw)
. 1996 Nov 1;88(9):3522-7.
Affiliations
- PMID: 8896419
Free article
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
G J Bosch et al. Blood. 1996.
Free article
Abstract
In chronic myeloid leukemia (CML) the classical 9;22 translocation results in a BCR-ABL fusion gene, which encodes chimeric BCR-ABL fusion 210 kD oncoproteins (p210BCR-ABL). The two main p210BCR-ABL fusion variants in CML, b2a2 and b3a2 are examples of well characterized antigens expressed by malignant cells. The possibility of an immunotherapeutic approach involving the fusion part of p210BCR-ABL in CML has previously been illustrated by observed peptide binding to major histocompatibility complex (MHC) class I alleles and by demonstrating the immunogenicity of p210BCR-ABL breakpoint peptides. In this report we show that in vitro immunization of human T cells with a 17 amino acid (aa) peptide representing the p210BCR-ABL fusion region resulted in peptide specific CD4+ T-cell lines designated P4, P6, and P7. HLA DR4 (DRB1*0401) restricted T-cell line P4 and several subsequently derived clones recognized HLA-DRB1*0401 and p210b3a2-mRNA expressing blasts from an allogeneic patient with CML in blast crisis. Recognition appeared DR expression-dependent. No responses were observed with DR4 positive p210BCR-ABL negative cells or with p210b3a2 leukemic cells with absent or insufficient expression of DR4. These observations indicate that oncoprotein p210b3a2 can be degraded and processed for presentation by MHC class II molecules at the surface of leukemic cells. The BCR-ABL fusion region is in all likelihood presented as peptides by HLA DR and thus capable to act as a distinctive tumor antigen to peptide specific CD4+ T cells.
Similar articles
- A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct.
ten Bosch GJ, Kessler JH, Joosten AM, Bres-Vloemans AA, Geluk A, Godthelp BC, van Bergen J, Melief CJ, Leeksma OC. ten Bosch GJ, et al. Blood. 1999 Aug 1;94(3):1038-45. Blood. 1999. PMID: 10419896 - CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S. Yasukawa M, et al. Blood. 1998 Nov 1;92(9):3355-61. Blood. 1998. PMID: 9787173 - HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S. Yasukawa M, et al. Blood. 2001 Sep 1;98(5):1498-505. doi: 10.1182/blood.v98.5.1498. Blood. 2001. PMID: 11520800 - T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ. Cheever MA, et al. Ann N Y Acad Sci. 1993 Aug 12;690:101-12. doi: 10.1111/j.1749-6632.1993.tb44000.x. Ann N Y Acad Sci. 1993. PMID: 8103658 Review. - Chronic myeloid leukemia as an immunological target.
Lim SH, Coleman S. Lim SH, et al. Am J Hematol. 1997 Jan;54(1):61-7. doi: 10.1002/(sici)1096-8652(199701)54:1<61::aid-ajh9>3.0.co;2-2. Am J Hematol. 1997. PMID: 8980262 Review.
Cited by
- MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy.
Hu Z, Zhang Q, He Z, Jia X, Zhang W, Cao X. Hu Z, et al. Front Immunol. 2024 Jun 7;15:1421092. doi: 10.3389/fimmu.2024.1421092. eCollection 2024. Front Immunol. 2024. PMID: 38911856 Free PMC article. Review. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens.
Weber D, Ibn-Salem J, Sorn P, Suchan M, Holtsträter C, Lahrmann U, Vogler I, Schmoldt K, Lang F, Schrörs B, Löwer M, Sahin U. Weber D, et al. Nat Biotechnol. 2022 Aug;40(8):1276-1284. doi: 10.1038/s41587-022-01247-9. Epub 2022 Apr 4. Nat Biotechnol. 2022. PMID: 35379963 Free PMC article. - Identification of neoantigens for individualized therapeutic cancer vaccines.
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Lang F, et al. Nat Rev Drug Discov. 2022 Apr;21(4):261-282. doi: 10.1038/s41573-021-00387-y. Epub 2022 Feb 1. Nat Rev Drug Discov. 2022. PMID: 35105974 Free PMC article. Review. - Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.
Hinterbrandner M, Rubino V, Stoll C, Forster S, Schnüriger N, Radpour R, Baerlocher GM, Ochsenbein AF, Riether C. Hinterbrandner M, et al. JCI Insight. 2021 Dec 8;6(23):e151797. doi: 10.1172/jci.insight.151797. JCI Insight. 2021. PMID: 34727093 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous